DOCSLIB.ORG

Switzerland Fund A-Chf 30 June 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Switzerland Fund A-Chf 30 June 2021 QPR.en.xx.20210630.LU0054754816.pdf For Investment Professionals Only FIDELITY FUNDS QUARTERLY PERFORMANCE REVIEW SWITZERLAND FUND A-CHF 30 JUNE 2021 Portfolio manager: Andrea Fornoni, Alberto Chiandetti Performance over quarter in CHF (%) Performance for 12 month periods in CHF (%) Fund 10.0 Market index 9.5 MSCI Switzerland Index (Net) Market index is for comparative purposes only. Source of fund performance is Fidelity. Basis: nav-nav with income reinvested, in CHF, net of fees. Other share classes may be available. Please refer to the prospectus for more details. Fund Index Market Environment European markets rose strongly over the second quarter, supported by improving sentiment around an economic reopening, strong economic data and upbeat corporate earnings, coupled with continued assurances of support from the European Central Bank (ECB). A decline in new COVID-19 cases and an acceleration in vaccine rollouts led to a gradual lifting of restrictions across the region. However, the spread of the Delta variant of COVID-19 tempered optimism towards the end of the quarter. With the global recovery picking up steam, worries about inflation and fears that central banks would taper their asset purchase programmes, as well as the US Federal Reserve’s more aggressive tone kept market gains in check. Against this backdrop, most sectors reported positive returns, with a decline in bond yields helping growth stocks to outperform value stocks. Fund Performance Over the quarter, the fund (A-CHF, net of fees) delivered positive returns of 10.0%, outperforming the MSCI Switzerland (N) index, which returned 9.5%. Strong security selection in health care and materials supported performance. Meanwhile, the overweight stance in the industrials sector weighed on returns. Key health care names enhanced gains The holding in hearing aid equipment manufacturer Sonova was the most notable contributor to performance. Its shares rallied on healthy FY20 results and as management raised its guidance for the year. The company has managed to control costs and new launches in its cochlear implant business are supporting growth. Sonova’s decision to acquire Sennheiser was also well received by the market. Shares in dental implants manufacturer Straumann Holdings supported performance. Its shares rallied after it beat consensus estimates for first quarter sales, driven by significant outperformance across regions. The company also raised its full-year organic growth guidance, buoyed by its strong market backdrop, high consumer confidence and supportive trends in specialty dental treatments. Meanwhile, the bias against pharmaceuticals giant Novartis added value. Certain names pared returns The underweight stance in pharmaceuticals giant Roche pared gains. Reports that Roche’s Tecentriq boosts disease-free survival in a cancer study supported investor sentiment. Positions in market expansion services provider DKSH Holding and Swiss insurer Baloise Holding were also a source of weakness. Fund Positioning We continue to focus on companies with high quality business models and management teams. The fund maintains a sizable allocation to the health care, industrials, financials and materials sectors in absolute terms. Relative to the index, it retains an underweight stance in consumer staples and health care, and an overweight exposure to industrials and financials. In recent months, the manager sold operationally/financially levered businesses given increased uncertainty in favour of reasonably valued high-quality businesses. Stock picking based on current environment Over the quarter, no new positions were bought or sold. However, we increased our exposure to Aryzta, a food business specialising in frozen bakery. The stock is well suited to benefit from the easing of virus-related restrictions. The allocation to luxury goods giant Richemont and watch manufacturer Swatch Group were increased. The current acceleration in demand for jewellery and watches should support both these stocks. Prefer selected health care companies Within health care, pharmaceutical giants Novartis and Roche are key holdings in the portfolio. Dental implants manufacturer Straumann Holdings and hearing aid manufacturer Sonova also remain attractive positions. Important Information Past performance is not a reliable indicator of future results. The fund's returns can be affected by fluctuations in currency exchange rates. The value of investments and any income from them may go down as well as up and an investor may not get back the amount invested. The use of financial derivative instruments may result in increased gains or losses within the fund. QPR.en.xx.20210630.LU0054754816.pdf For Investment Professionals Only FIDELITY FUNDS QUARTERLY PERFORMANCE REVIEW SWITZERLAND FUND A-CHF 30 JUNE 2021 Attribution Performance attribution is produced in the currency shown below. For funds with multiple share classes, the attribution return reflects the aggregate performance across all the share classes. It may therefore deviate from the published return for a particular share class. When using the analysis for hedged share classes, please consider that the attribution is shown before the impact of hedging. The contributions shown in the tables are before the impact of charges. If charges are applied, their effect is captured in the “Other” category in the tables and will also be reflected in the fund return. All investments, including derivatives, linked to a particular issuing company have been combined to form a total percentage for each issuing company. The sector/industry and geographic contribution tables (where relevant) display a maximum of eleven individual entries. Where applicable, only top five and bottom five are listed, with the remaining contribution shown in the "Other Sectors" or “Others” category. Currency of attribution Swiss Franc (CHF) Three month relative return (%) 0.99 Position Contribution (%) 3 months Average Relative Average Relative Relative Performance Relative Performance TOP CONTRIBUTORS Weight Contribution TOP DETRACTORS Weight Contribution SONOVA HLDG AG 3.7 1.01 ROCHE HOLDING AG -10.3 -0.49 STRAUMANN HOLDING AG 3.0 0.44 DKSH HOLDING AG 3.6 -0.45 NOVARTIS AG -7.5 0.40 BALOISE HOLDINGS AG 1.9 -0.36 BOSSARD HLDG AG 1.3 0.33 OC OERLIKON CORP AG 1.9 -0.28 ALCON INC -2.2 0.27 VZ HOLDING AG 2.4 -0.20 SIG COMBIBLOC SERVICES AG 3.0 0.22 NESTLE SA -12.3 -0.20 ARYZTA AG 1.8 0.21 AMS AG 1.5 -0.19 PARTNERS GROUP HOLDING 2.3 0.19 SWISS RE AG 1.1 -0.18 GIVAUDAN SA 2.1 0.18 SCHINDLER HOLDING AG 1.1 -0.13 HOLCIM LTD -2.0 0.12 GEBERIT AG -1.6 -0.11 Positions in other funds - including ETFs (Exchange Traded Funds) - can appear in this table, but index derivatives form part of an "Index / Unclassified" category which will appear in the table(s) below when relevant. Sector/Industry Contribution (%) 3 months CONTRIBUTIONS TO RELATIVE RETURN Average Sector/ Total Relative Security Industry Relative GICS Sector Weight Selection Selection Contribution Health Care -9.8 1.05 0.45 1.51 Materials 4.8 0.35 0.29 0.63 Consumer Discretionary 3.4 -0.14 0.22 0.08 Communication Services -0.9 0.00 0.02 0.02 Real Estate -0.5 0.00 0.02 0.02 Consumer Staples -12.3 0.21 -0.20 0.01 Information Technology 3.2 -0.15 -0.03 -0.19 Financials 4.8 0.20 -0.44 -0.23 Industrials 5.8 0.25 -1.05 -0.80 Index / Unclassified 0.3 0.00 0.00 0.00 Total Primary Assets -1.2 1.77 -0.72 1.05 Other* 1.2 -0.06 TOTAL 0.0 0.99 *Other includes portfolio components not already listed such as cash, expenses and other miscellaneous items. QPR.en.xx.20210630.LU0054754816.pdf For Investment Professionals Only FIDELITY FUNDS QUARTERLY PERFORMANCE REVIEW SWITZERLAND FUND A-CHF 30 JUNE 2021 Important Information This information must not be reproduced or circulated without prior permission. Fidelity International refers to the group of companies which form the global investment management organisation that provides information on products and services in designated jurisdictions outside of North America. Fidelity only offers information on its own products and services and does not provide investment advice based on individual circumstances, other than when specifically stipulated by an appropriately authorised firm, in a formal communication with the client. This communication is not directed at, and must not be acted upon by persons inside the United States and is otherwise only directed at persons residing in jurisdictions where the relevant funds are authorised for distribution or where no such authorisation is required. Unless otherwise stated all products and services are provided by Fidelity International, and all views expressed are those of Fidelity International. Fidelity, Fidelity International, the Fidelity International logo and F symbol are registered trademarks of FIL Limited. Morningstar annualised growth rates, total return, sector median performance and ranks - Data Source - © 2021 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Before investing you should read the key information document, which is available in your local language through the website www.fidelityinternational.com or from your distributor. Austria: Investments should be made on the basis of the current prospectus/Key Investor Information Document (KIID), which is available along with the current annual and semi-annual reports free of charge from our European Service Centre in Luxembourg, FIL (Luxembourg) S.A. 2a, rue Albert Borschette BP 2174 L-1021 Luxembourg as well as with the Austrian paying agent UniCredit Bank Austria AG, Schottengasse 6-8, 1010 Wien, FIL (Luxembourg) S. A. – Zweigniederlassung Wien, Mariahilfer Strasse 36, 1070 Wien or www.fidelity.at.
Load more

Recommended publications
  • 2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2
    2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 CONTENTS #TogetherStrong Highlights 3 #TogetherStrong is a tag-name that covers #TogetherStrong aptly describes how we countless initiatives we took to address progressed through and emerged from this Letter to shareholders 7 pressing needs in the dental community extraordinary year. Management commentary 11 in 2020. Straumann Group in brief 12 Strategy in action 17 #TogetherStrong is forward-looking; it Products, solutions and services 21 It started with a website offering scientific expresses purpose, teamwork, courage, Innovation 26 and practical information to help Markets 29 determination, perseverance, moving Business performance (Group) 35 customers and staff through the corona forward and succeeding in turbulent Business performance (Regions) 38 virus crisis. Soon it became a holistic, Business performance (Financials) 44 surroundings – themes that are captured Share performance 46 omni-channel response including a in the pictures and contents of this report. Risk management 49 massive education platform. Sustainability report 57 The #TogetherStrong concept has Corporate governance 80 extended to thousands of activities Compensation report 107 and millions of communications. It demonstrates how the events of 2020 Financial report 123 fuelled our resourcefulness, innovation Appendix 184 and passion for creating opportunities. Global Reporting Initiative (GRI) 185 GRI content
    [Show full text]
  • DWS (CH) II Small and Mid Caps Switzerland
    Marketing Material DWS (CH) II Small and Mid Caps Switzerland Equity Funds - Europe - Regions/Countries August 2021 As at 31/08/2021 Fund Data Performance Investment Policy Performance - Share Class FD (in %) The goal of the sub-fund is primarily to achieve long-term growth in Swiss Francs through investment in a portfolio of stocks from Swiss issuers that are listed in a representative Swiss equities index of small and medium enterprises or the small and mid- cap subindex of a Swiss equities index (“the benchmark”). The investment strategy is based on a transparent and comprehensible investment process, focuses on stock selection. Fund Benchmark (since 09/08/2006): SPI EXTRA Total Return (RI) Past performance is no indication of current or future performance, and the performance data do not take account of the commissions and costs Fund Management's Comment incurred on the issue and redemption of units. For detailed comments on the fund and its corresponding markets please see the annual report. Cumulative performance (in %) - share class FD 1 m 1 y 3 y 5 y s. Inception YTD 3 y avg 5 y avg 2017 2018 2019 2020 CHF 3.0 42.7 36.1 77.7 421.8 29.6 10.8 12.2 29.9 -21.6 29.3 1.8 EUR 2.7 42.0 42.2 80.2 650.5 30.2 12.5 12.5 19.4 -18.6 33.7 2.2 BM IN CHF 2.5 34.9 39.1 90.5 284.2 23.7 11.6 13.8 29.7 -17.2 30.4 8.1 Further Characteristics (3 years) / VAR (1 year) - share class FD Volatility 18.36% Maximum Drawdown -21.26% VAR (99%/10 days) 7.23% Sharpe Ratio -- Information Ratio -0.16 Correlation Coefficient 0.97 Alpha -1.26% Beta 1.05 Tracking Error
    [Show full text]
  • Market Notice Date: 14 November 2019 Market Notice Number: 112/2019
    Market Notice Date: 14 November 2019 Market Notice Number: 112/2019 Equiduct Universe Change Please see today's changes below effective 18 November 2019: Trading Reporting MIC Settlement Trading Settlement Tick Size Change/ Security Name ISIN Home Market Symbol Country Currency Currency table Action ABB LTD ABBNz CH0012221716 XSWX EQTB CH CHF CHF ESMA_E Deletion ABB ABBs CH0012221716 XSTO EQTB SE SEK SEK ESMA_E Deletion ADECCO SA ADENz CH0012138605 XSWX EQTC CH CHF CHF ESMA_E Deletion AMS AG AMSz AT0000A18XM4 XSWX EQTC CH CHF CHF ESMA_E Deletion ARYZTA AG ARYNz CH0043238366 XSWX EQTB CH CHF CHF ESMA_E Deletion JULIUS BAER GRUPPE AG BAERz CH0102484968 XSWX EQTC CH CHF CHF ESMA_E Deletion BALOISE-HLDGS BALNz CH0012410517 XSWX EQTC CH CHF CHF ESMA_D Deletion BARRY CALLEBAUT AG BARNz CH0009002962 XSWX EQTC CH CHF CHF ESMA_D Deletion BB BIOTECH BBZAd CH0038389992 XETR EQTB DE EUR EUR ESMA_D Deletion BB BIOTECH BIONz CH0038389992 XSWX EQTB CH CHF CHF ESMA_D Deletion BASILEA PHARMACEUTICA AG BSLNz CH0011432447 XSWX EQTC CH CHF CHF ESMA_D Deletion BUCHER INDUSTRIES BUCNz CH0002432174 XSWX EQTC CH CHF CHF ESMA_D Deletion COMPAGNIE FINANCIERE RICHEMONT CFRz CH0210483332 XSWX EQTC CH CHF CHF ESMA_E Deletion CLARIANT CLNz CH0012142631 XSWX EQTC CH CHF CHF ESMA_E Deletion CEMBRA MONEY BANK AG CMBNz CH0225173167 XSWX EQTC CH CHF CHF ESMA_D Deletion CREDIT SUISSE GROUP AG CSGNz CH0012138530 XSWX EQTC CH CHF CHF ESMA_E Deletion DKSH HOLDING DKSHz CH0126673539 XSWX EQTC CH CHF CHF ESMA_D Deletion DORMA+KABA HOLDING AG DOKAz CH0011795959 XSWX EQTC CH CHF
    [Show full text]
  • Longer Term Investments Medical Devices
    Longer Term Investments Medical devices Chief Investment Office GWM | 11 April 2019 6:53 pm BST Lachlan Towart, Analyst; Stefan R Meyer, Analyst • The aging population and growth of the over-65 age group will create more opportunities for companies selling medical products and devices. • Other drivers of this industry include better penetration in emerging markets due to improved infrastructure, innovative new treatments, increased affordability due to rising per-capita GDP and a growing prevalence of "lifestyle diseases" such as obesity due to urbanization. • We identified five key markets for implantable or wearable devices, including consumer products such as hearing aids, dental implants and corrective lenses. We estimate their total market size at USD 114.8bn with a rate of potential growth in the mid-single digits. • The theme is relatively defensive and should appeal to quality- focused investors. We recommend exposure to it via a diversified portfolio of stocks across our preferred markets and segments. Medical devices can assist in the treatment of many conditions. Some reduce the risk of a treated condition worsening, perhaps as an alternative to drug therapy; others improve users' quality of life or functionality; and still others can solve problems untreatable with drugs. Devices like joint replacements effectively offer permanent long-term solutions (i.e. a cure). Medical devices are primarily used by the over-65 age group, whose growth will outpace the broader population's over the coming decades. Demand is also supported by the rise of "lifestyle diseases" like obesity, itself related to urbanization. The medical device industry has matured, but still represents a substantial opportunity, in our view.
    [Show full text]
  • Contract Specifications for Futures Contracts and Eurex14 Options Contracts at Eurex Deutschland and Stand March 2831, 2008 Eurex Zürich Seite 1
    Contract Specifications for Futures Contracts and Eurex14 Options Contracts at Eurex Deutschland and Stand March 2831, 2008 Eurex Zürich Seite 1 [....] Annex A in relation to subsection 1.6 of the contract specifications: Futures on Shares of Produkt- Group Cash Contract Minimum Currency ID ID** Market- Size Price ID** Change* Julius Bär Holding AG - N. BAEG CH01 XSWX 50 0.0010.01 CHF BB Biotech AG BIOF CH01 XSWX 50 0.0010.01 CHF Logitech International S.A. - N. LOGF CH01 XSWX 100 0.00010.01 CHF Pargesa Holding S.A. PARF CH01 XSWX 10 0.0010.01 CHF Sonova Holding AG - N. PHBF CH01 XSWX 50 0.0010.01 CHF PSP Swiss Property AG - N. PSPF CH01 XSWX 50 0.0010.01 CHF Schindler Holding AG SINF CH01 XSWX 50 0.0010.01 CHF Straumann Holding AG STMF CH01 XSWX 10 0.0010.01 CHF Swatch Group AG, The - N. UHRF CH01 XSWX 100 0.00010.01 CHF Valiant Holding AG - N. VATF CH01 XSWX 10 0.0010.01 CHF ABB Ltd. ABBF CH02 XVTX 100 0.00010.01 CHF Adecco S.A. - N. ADEF CH02 XVTX 100 0.0010.01 CHF Actelion Ltd. - N. ATLG CH02 XVTX 50 0.0010.01 CHF Bâloise Holding AG BALF CH02 XVTX 100 0.0010.01 CHF Compagnie Financière Richemont AG CFRH CH02 XVTX 100 0.0010.01 CHF Ciba Spezialitätenchemie Holding AG - N. CIBF CH02 XVTX 10 0.0010.01 CHF Clariant AG - N. CLNF CH02 XVTX 100 0.00010.01 CHF Credit Suisse Group - N. CSGG CH02 XVTX 100 0.00010.01 CHF Geberit AG - N.
    [Show full text]
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • Corporate Governance
    Business report Corporate governance Transparency is one of the key elements of good corporate governance, to which Sonova is committed. Good corporate governance is essential for Sonova and we strive for high standards in this field. What “good corporate governance” means is an evolving matter and we constantly monitor the latest changes to the requirements. Compliance is an integral element of our corporate culture and embedded in our core values. We therefore continued to strengthen the Sonova Group compliance program during the 2017/18 financial year, putting particular emphasis on integrating our acquired businesses into our compliance culture, designing new global compliance training, and updating our antibribery policy. Our continuing compliance efforts help us to live our values of ethical behavior and unquestionable integrity. At Sonova, corporate governance is based upon, and structured to conform with, relevant standards and practices. The company fulfils its legal duties under the Swiss Code of Obligations, the SIX Swiss Exchange Directive on Information relating to Corporate Governance, and the standards defined in the Swiss Code of Best Practice for Corporate Governance. This report describes the principles of corporate governance for the Sonova Group and provides background information on the Group’s executive officers and bodies as of March 31, 2018. All relevant documents can be accessed at the corporate governance section of the Sonova website: www.sonova.com/en/commitments/corporategovernance. For clarity and transparency, the compensation report is presented as a separate chapter of the annual report. Sonova Annual Report 2017/18 37 CORPORATE GOVERNANCE Group structure Operational group structure The Sonova Group is headquartered in Stäfa, Switzerland, and is active in over 100 countries.
    [Show full text]
  • Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
    Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation
    [Show full text]
  • Bekanntmachung Auf Keyinvest Bezugsrechtsemission AMS AG
    Bekanntmachung auf KeyInvest Bezugsrechtsemission AMS AG Rights issue AMS AG Im Zusammenhang mit der Kapitalerhöhung der AMS AG (Bloomberg Code: AMS SE) durch Bezugsrechtsemission wurden die Bedingungen der unten genannten Produkte der UBS AG, per 16. März 2020 angepasst. Die detaillierten Informationen befinden sich in der entsprechenden Produktedokumentation (Termsheets). With regard to the rights issue of AMS AG (Bloomberg Code: AMS SE), UBS AG will adjust the terms of the following products as of 16th March 2020. Detailed information can be found in the respective product documentation (Termsheets). ISIN Name CH0406766680 PERLES Plus on AMS AG CH0434739725 Kick-In Certificate on AMS AG / U-Blox / ABB CH0434739717 Kick-In Certificate on AMS AG / U-Blox / ABB CH0524660716 8.40% p.a. Callable Kick-In GOAL on AMS AG / Logitech / Temenos CH0391676241 PERLES Plus on AMS AG CH0405218907 PERLES Plus on AMS AG CH0428536335 9.00% p.a. ER Worst of Kick-In GOAL on AMS AG / Temenos / OC Oerlikon CH0437181537 Kick-In Certificate on AMS AG / Autoneum Holding AG / Dufry AG CH0524663124 10.20% p.a. ER Kick-In GOAL on AMS AG CH0522755518 6.00% p.a. Callable Kick-In GOAL on AMS AG / Kühne + Nagel / Swatch I / Richemont / LafargeHolcim CH0509384506 6.496023402505% p.a. Kick-In GOAL on AMS AG / Credit Suisse / Swiss Re CH0512543437 FACTOR CERTIFICATE ON AMS AG CH0512543445 FACTOR CERTIFICATE ON AMS AG CH0512547974 FACTOR CERTIFICATE ON AMS AG CH0527058983 FACTOR CERTIFICATE ON AMS AG CH0453246909 CHF MINI-FUTURE ON AMS AG CH0521942109 CHF EQUITY-WARRANT
    [Show full text]
  • First-Quarter 2021 Report – Media Release
    First-quarter 2021 report – Media Release Straumann Group reports very strong first-quarter sales results accelerated by product launches and consumer focus on oral health . Record quarterly revenue of CHF 470 million, 34% organic growth compared to previous year which was already impacted by the pandemic . Acquisition effect of 2% due to DrSmile . Recent investments and product launches driving growth, performance lifted by strong consumer focus on oral health . Strong organic double-digit growth in all regions; contributions led by the largest regions EMEA and North America . Investment of CHF 170 million by 2029 in China Campus to support future growth . Full-year 2021 outlook raised to organic revenue growth in the mid-to-high twenties percentage range expecting an improvement in profitability (core EBIT margin) compared to 2020 REVENUE BY REGION Q1 2021 Q1 2020 (in CHF million) Europe, Middle East & Africa (EMEA) 214.3 162.2 Change in CHF in % +32.1 0.9 Change in local currencies in % +33.1 7.5 Change organic1 in % +27.0 0.1 % of Group total 45.6 45.4 North America (NAM) 138.0 115.7 Change in CHF in % +19.4 4.9 Change in local currencies in % +27.0 7.9 Change organic1 in % +27.0 7.7 % of Group total 29.4 32.4 Asia Pacific 92.3 53.5 Change in CHF in % +72.4 -25.5 Change in local currencies in % +74.4 -21.7 Change organic1 in % +74.4 -22.1 % of Group total 19.6 15.0 Latin America 25.2 26.0 Change in CHF in % -3.1 -12.0 Change in local currencies in % +23.8 7.3 Change organic1 in % +23.8 7.2 % of Group total 5.4 7.3 GROUP 469.8 357.3 Change in CHF in % +31.5 -4.0 Change in local currencies in % +37.0 1.9 Change organic1 in % +34.0 -1.4 1 Excluding the effects of currencies and acquisitions Page 1/6 Basel, April 29, 2021: The Straumann Group made an exceptional start to 2021 and the solid growth trend experienced in the second half of 2020 accelerated.
    [Show full text]
  • Annual Report 2018 19 Table of Content
    FINANCIAL REPORT Annual Report 2018 19 Table of content Letter to shareholders 2 Our product and service offering 6 Strategy and businesses 10 Corporate governance 36 Compensation report 60 Financial review 96 5 year key figures 104 Consolidated financial statements 105 Financial statements of Sonova Holding AG 175 Investor information 188 Corporate Responsibility Report 190 Letter to shareholders Dear shareholders, 2018/19 marked another year of solid financial performance, posting further record levels of sales and profits to which all three businesses contributed. Moreover – and as expected – growth accelerated from the first half-year to the second, driven by the launch of a number of innovative products and solutions. Sonova affirmed its leading position in audiological performance with the release of the Marvel™ technology platform. Marvel takes full advantage of the unique connectivity enabled by our SWORD™ (Sonova Wireless One Radio Digital) chip and combines it with the proven convenience of our rechargeable solutions. We also made significant progress in our retail business, which we have renamed “audiological care” for one simple reason: care is what we deliver. The expert service We have made significant provided by our hearing care professionals adds key value for the consumer. progress in implementing our strategy. Our cochlear implants business launched a series of innovative new products to strengthen its leading position in this expanding market. Robert Spoerry You will find details of these and other strategic initiatives in the “strategy and businesses” section of this report. The global market in which we operate is poised for further growth, as developed countries see increasing demand from the “baby boomer” generation and developing countries begin to bridge the gap in hearing care provision.
    [Show full text]
  • FACTSHEET - AS of 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR
    FACTSHEET - AS OF 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR HISTORICAL PERFORMANCE 6,000 5,000 4,000 3,000 2,000 1,000 Jan-2000 Jan-2005 Jan-2010 Jan-2015 Jan-2020 Solactive Switzerland 40 Equal Weight Index TR CHARACTERISTICS ISIN / WKN DE000SLA98V4 / SLA98V Base Value / Base Date 1000 Points / 03.03.1999 Bloomberg / Reuters SOCH40ET Index / .SOCH40ET Last Price 5520.10 Index Calculator Solactive AG Dividends Included Index Type Total Return Calculation 09:00am to 10:30pm (CET), every 60 seconds Index Currency CHF History Available daily back to 03.03.1999 Index Members 40 FACTSHEET - AS OF 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -6.87% -1.29% 6.88% 26.84% 16.30% 452.01% Performance (p.a.) - - - - - 7.86% Volatility (p.a.) 14.33% 11.91% 11.14% 12.42% 11.49% 18.86% High 5927.07 5927.07 5927.07 5927.07 5927.07 5927.07 Low 5498.67 5498.67 5111.72 4101.40 4734.43 549.01 Sharpe Ratio -4.04 -0.43 1.30 2.20 1.96 0.42 Max. Drawdown -7.23% -7.23% -7.23% -8.17% -7.23% -68.82% VaR 95 \ 99 -22.5% \ -33.9% -29.8% \ -57.3% CVaR 95 \ 99 -29.9% \ -44.8% -47.2% \ -78.4% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES CH 97.6% CHF 100.0% AT 2.4% TOP COMPONENTS AS OF 29-Sep-2021 Company Ticker Country Currency Index Weight (%) DUFRY AG DUFN SE Equity CH CHF 2.80% SWISSCOM AG SCMN SE Equity CH CHF 2.69% ALCON INC ALC SE Equity CH CHF 2.67% SONOVA HOLDING AG SOON SE Equity CH CHF 2.64% UBS GROUP AG UBSG SE Equity CH CHF 2.63% JULIUS BAER GRUPPE AG BAER SE Equity CH CHF 2.61% KUEHNE & NAGEL INTERNATIONAL AG KNIN SE Equity CH CHF 2.60% NESTLE SA NESN SE Equity CH CHF 2.60% SWISS LIFE HOLDING AG SLHN SE Equity CH CHF 2.60% CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG LISP SE Equity CH CHF 2.60% FACTSHEET - AS OF 29-Sep-2021 Solactive Switzerland 40 Equal Weight Index TR DISCLAIMER © Solactive AG, 2021.
    [Show full text]